溴芬酸钠
| 中文名称 | 溴芬酸钠 |
|---|---|
| 中文同义词 | 溴酚酸钠;溴芬那酸钠水合物;溴芬酸钠水合物;溴芬酸钠;溴芬那酸钠;(2-氨基-3-(4-溴苯甲酰)苯基)乙酸钠;(2-氨基-3-(4-溴苯甲酰)苯基)乙酸钠水合物;溴芬酸钠120638-55-3 |
| 英文名称 | Bromfenac Sodium |
| 英文同义词 | bromfenac sodium salt sesquihydrate;Benzeneacetic acid,2-amino-3-(4-bromobenzoyl)-,sodium salt,hydrate(2:2:3);Bromfenac sodiu;Sodium (2-amino-3-(4-bromobenzoyl)phenyl)acetate;Benzeneacetic acid, 2-amino-3-(4-bromobenzoyl)-, monosodium salt, hydrate (2:3);Bromfenac ophthalmic;Bromfenac ophthalmic solution;Duract |
| CAS号 | 120638-55-3 |
| 分子式 | C15H11BrNNaO3 |
| 分子量 | 356.15 |
| EINECS号 | 695-342-6 |
| 相关类别 | 小分子抑制剂;有机原料;小分子抑制剂，天然产物;眼科用药;医药 眼科用药;医药原料;原料药;生物活性分子-API;Intermediates & Fine Chemicals;Pharmaceuticals;Inhibitors;API |
| Mol文件 | 120638-55-3.mol |
| 结构式 |  |
溴芬酸钠 性质
| 熔点 | 268-270°C (dec.) |
|---|---|
| 储存条件 | Refrigerator |
| 溶解度 | DMSO：≥100mg/mL（260.98mM）；水：≥100mg/mL（260.98mM） |
| 形态 | 固体 |
| 颜色 | 浅黄至黄色 |
| InChI | InChI=1S/C15H12BrNO3/c16-11-6-4-9(5-7-11)15(20)12-3-1-2-10(14(12)17)8-13(18)19/h1-7H,8,17H2,(H,18,19) |
| InChIKey | ZBPLOVFIXSTCRZ-UHFFFAOYSA-N |
| SMILES | C1(=CC=CC(CC(=O)O)=C1N)C(=O)C1=CC=C(Br)C=C1 |
溴芬酸钠是一种溴化非甾体类抗炎/镇痛药 (NSAID)，通常用于白内障手术后的术后炎症和疼痛以及假晶状体囊状黄斑水肿 (CME) 的研究。
溴芬酸钠是一种有效的和具有口服活性的 COX 抑制剂，抑制 COX-1 和 COX-2 的 IC50 值分别为 5.56 和 7.45 nM。
|
COX-1 5.56 nM (IC 50 ) |
COX-2 7.45 nM (IC 50 ) |
Bromfenac (90 μg/mL; 48 h) inhibits TGF-b1-induced extracellular matrix (ECM) synthesis and myofibroblast activation in HConFs and HPFs.
Bromfenac (30-90 μg/mL; 48 h) decreases the protein and mRNA expression levels of FN, COL3, a-SMA, and survivin in a dose-dependent manner in HConFs and HPFs.
Bromfenac (30-90 μg/mL; 48 h) declines the phosphorylated protein levels of AKT, ERK1/2, and GSK-3b-S9 with dosage in HPFs and HConFs.
Bromfenac (0.0032-3.16%; 100 or 200 μL; rubbed onto the backs) produces significant anti-inflammatory activity at concentrations as low as 0.1% (4 h pretreatment time) or 0.32% (18h pretreatment time) in rats.
Bromfenac (0.032-3.16%; 100 μL; rubbed onto the paws) produces dose-related anti-inflammatory activity in rats.
Bromfenac (0.032-1.0%; 50 μL) is 26 times more potent than indomethacin in blocking the erythema when applied directly onto the skin area exposed to UV light in guinea pigs.
Bromfenac (0.0032-0.1%; 50μL; rubbed onto the uninjected paw for 4 h per day and 5 days per week) produces a dose and time dependent reduction in the paw volume of both hind limbs in rats.
Bromfenac (0.32%; 50μL; rubbed onto the abdomen) produces significant blockade of abdominal constriction to ACh challenge in mice.
| Animal Model: | Male Sprague-Dawley rats (150-250 g) are injected carrageenan |
| Dosage: | 0.0032, 0.01, 0.032, 0.1, 0.32, 1.0, 3.16% (100 or 200 μL) |
| Administration: | Rubbed onto the backs before 1-72 h of injected carrageenan |
| Result: |
Produced significant anti-inflammatory activity when applied 1, 2, and 4 h prior to carrageenan challenge at 0.32%.
Applied 1 or 4 h prior to carrageenan challenge was active, but not when applied 24 h (or longer) prior to challenge at 0.2%. |
安全信息
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2025/05/22 | HY-B1888B | (2-氨基-3-(4-溴苯甲酰)苯基)乙酸钠 Bromfenac sodium hydrate | 120638-55-3 | 5 mg | 225元 |
| 2025/05/22 | HY-B1888B | (2-氨基-3-(4-溴苯甲酰)苯基)乙酸钠 Bromfenac sodium hydrate | 120638-55-3 | 10mM * 1mLin DMSO | 248元 |